Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Chris Pihl
AddedMar 31, 2024
UpdatedMay 31, 2026
Chris Pihl

Chris Pihl

Unknown, Helion Energy

CrunchbaseLinkedIn

Chris Pihl's Career

Helion Energy
Helion Energy

Everett, WA, US

Unknown
Sigma Genetics
Sigma Genetics

Seattle, WA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Chris Pihl's Career

Helion Energy
Helion Energy
Series E$577.8M2002013Everett, WA, US
Unknown

Recent news

Sam Altman-backed fusion startup Helion in talks to sell power to OpenAITechCrunch · 2026
Fusion startup Helion hits blistering temps as it races toward 2028 deadlineTechCrunch · 2026
Sam Altman's fusion startup Helion Energy hits 150 million degree plasma temperature—a milestone that could bring first grid power in 2028Fortune · 2026

Leadership at Helion Energy

George VotroubekGeorge VotroubekCo-Founder
Sam AltmanSam AltmanBoard Member
David KirtleyDavid KirtleyCo-Founder
Sigma Genetics
Sigma Genetics
Seed$120k62016Seattle, WA, US
Founder

Leadership at Sigma Genetics

Matthew ScholzMatthew ScholzBoard Member
Zachary R.Zachary R.Co-Founder

Similar to Sigma Genetics

ExcepgenExcepgenSan Francisco, CA, USGene Therapies, Vaccinesest. 2018ExcepgenSan Francisco, CA, US · est. 2018

ExcepGen: A San Francisco-based biotech firm innovating in drug discovery for next-gen therapeutics.

Seed · $4.2M6
Sixfold BioscienceSixfold BioscienceLondon, Greater London, GBest. 2018Sixfold BioscienceLondon, Greater London, GB · est. 2018

Sixfold Bioscience: Pioneering RNA therapy delivery with patented systems.

Seed · $10.6M33
SomagenicsSomagenicsSanta Cruz, CA, USDiagnostics, Therapeuticsest. 1997SomagenicsSanta Cruz, CA, US · est. 1997

SomaGenics: A Santa Cruz-based biotech firm specializing in innovative RNAi-based therapeutics and diagnostics.

Seed · $1.8M10
XGenomesXGenomesCambridge, MA, USDNA Sequencingest. 2017XGenomesCambridge, MA, US · est. 2017

XGenomes: Revolutionizing DNA sequencing with fast, accurate, and affordable technology for health monitoring.

Angel · $350k9

Chris Pihl's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Chris Pihl

David SmernoffDavid SmernoffCo-Founder · HelioBioSysIvan BallIvan BallCo-Founder · Hydro GrowChristie ObiayaChristie ObiayaCEO · HeliogenJohn O'SheaJohn O'SheaCo-Founder · Helgen TechnologiesArtem GermanovArtem GermanovCo-Founder · Souq G-Commerce